
    
      This is a single-center, open label pilot study. The study is comprised of 5 study visits;
      Screening, Baseline, and weeks 4,8, and 12. All subjects will receive Oracea once daily (QD)
      and Epiduo Forte at Baseline. WE will evaluate Investigator Global Assessment (IGA), total
      lesion count, adverse events and concomitant medications.
    
  